Dispatch Bio Announces First Patient Dosed in Phase I Study of DISP-10, a Novel Investigational Immunotherapy, in Advanced Gastrointestinal (GI) Cancers

Dispatch Bio announced the first participant has been dosed in a Phase I clinical trial evaluating the safety and efficacy of DISP-10 in adult participants with advanced gastrointestinal (GI) cancers.